Table 2. Comparison of SUVmax according to clinical characteristics.

	SUVmax	P
Gender		0.424
Male (n = 41)	9.7 (3.5–13.5)
Female (n = 13)	10.1 (7.0–13.5)
Histologic subtype		0.003
Epithelioid (n = 34)	5.5 (3.2–10.8)
Sarcomatoid/biphasic (n = 13)	11.7 (9.9–14.7)
NOS (n = 7)	13.3 (9.5–15.8)
Stage		0.031
Stage I–II (n = 20)	5.5 (3.4–10.8)
Stage III–IV (n = 34)	10.4 (7.3–13.7)
Surgery		0.037
Yes (n = 19)	5.1 (3.0–10.4)
No (n = 35)	10.3 (5.8–13.7)
Chemotherapy		0.565
Pemetrexed/platinum (n = 36)	9.1 (4.3–13.5)
None (n = 18)	10.3 (4.2–13.3)

Data are presented as median (interquartile range).

NOS, not otherwise specified; SUVmax, maximum standardized uptake value